Opendata, web and dolomites

Fucoderm

An effective, side effect-free topical emollient treatment for atopic dermatitis made from a sustainably procured seaweed extract

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Fucoderm project word cloud

Explore the words cloud of the Fucoderm project. It provides you a very rough idea of what is the project "Fucoderm" about.

track    mild    ad    lesions    comprise    saccharides    expertise    launch    glycobiology    moderate    maximising    reticent    opting    glycomar    drug    formulation    meet    commercialisation    skin    shortcomings       team    created    ingredient    chronic    rashes    disease    responds    extracted    inflammatory    child    unpleasant    commercial    pipeline    sufferers    pursuit    pharmaceutical    tend    consumers    topical    fucoidan    2019    extensive    nutraceutical    create    attracting    first    steroid    record    fucoderm    brown    active    grant    market    pharma    discovery    historically    90    cash    convenience    characterised    preferences    itchy    biotechnology    eczema    natural    4b    healthcare    dermatitis    creams    company    toxicity    profitability       maintenance    reaching    dilutive    immunomodulatory    atopic    adults    dominated    life    severe    negative    cosmetic    treatments    marine    collective    turn    seaweed    periods    successful    attributes    generative    quality    steroids    prescription    treatment   

Project "Fucoderm" data sheet

The following table provides information about the project.

Coordinator
GLYCOMAR LIMITED 

Organization address
address: DUNSTAFFNAGE MARINE LABOARATORY EUROPEAN CENTRE FOR MARINE BIOTECHNOLOGY DUNBEG ARGYLL
city: OBAN
postcode: PA37 1QA
website: www.glycomar.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.glycomar.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCOMAR LIMITED UK (OBAN) coordinator 50˙000.00

Map

 Project objective

Atopic dermatitis (AD), a chronic inflammatory skin disease characterised by itchy skin lesions and rashes, affects 1 child in 5-10, and 3% of adults. Without effective treatment it can have a severe negative impact on quality of life. Treatment has historically been dominated by topical steroid creams, although consumers – reticent to using steroids over long periods, and for convenience (some steroid treatments are prescription only) – are increasingly opting for non-pharma products with natural attributes. These natural products, however, tend to have high toxicity and therefore to create unpleasant side effects. Glycomar’s eczema treatment, Fucoderm, directly addresses these shortcomings and responds to consumer preferences. Using an active pharmaceutical ingredient extracted from brown seaweed – a Fucoidan – Glycomar has created a novel topical formulation for maintenance treatment. The product is the first commercial application of Glycomar’s extensive glycobiology expertise – the team has over 100 years’ collective experience in marine biotechnology and drug discovery/development – and it will be targeted towards mild- to moderate AD sufferers. Together these cases comprise 80-90% of the €4b market, which is growing at 3,8% – maximising potential impact. The company, which has been working for 10 years in pursuit of novel immunomodulatory saccharides, has a track record of attracting non-dilutive grant funding, and of creating cash generative, value enhancing partnerships. Successful commercialisation of Fucoderm would enable Glycomar to meet its target of reaching profitability by 2019, in turn facilitating the launch of other consumer healthcare, nutraceutical and cosmetic products in the development pipeline.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FUCODERM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FUCODERM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More